Biopharmaceutics & Drug Disposition 1985-01-01

Lack of effect of liver disease on the pharmacokinetics of acebutolol and diacetolol: a single dose study.

R Zaman, D B Jack, M R Wilkins, M J Kendall

Index: Biopharm. Drug Dispos. 6(2) , 131-7, (1985)

Full Text: HTML

Abstract

The pharmacokinetics of acebutolol and its major metabolite, diacetolol, following a single 400 mg oral dose, were investigated in patients with liver disease. No significant differences were found in any of the parameters measured.

Related Compounds

Related Articles:

Using supported liquid extraction together with cellobiohydrolase chiral stationary phases-based liquid chromatography with tandem mass spectrometry for enantioselective determination of acebutolol and its active metabolite diacetolol in spiked human plasma.

2009-01-15

[J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 877(3) , 173-80, (2009)]

Acebutolol: a review of its pharmacology, pharmacokinetics, clinical uses, and adverse effects.

1986-01-01

[Pharmacotherapy 6(2) , 45-63, (1986)]

Preliminary study of the disposition in man of acebutolol and its metabolite, diacetolol, using a new stereoselective hplc method.

1984-04-01

[J. Pharm. Pharmacol. 36(4) , 276-7, (1984)]

Enantioselective high performance liquid chromatographic assay of acebutolol and its active metabolite diacetolol in human serum.

1999-01-01

[Chirality 11(4) , 267-71, (1999)]

Displacement of [3H]dihydroalprenolol binding from rat heart and lung by acebutolol, diacetolol and D-diacetolol.

1983-03-01

[J. Pharm. Pharmacol. 35(3) , 198-9, (1983)]

More Articles...